Evidence map›Paper›PMID 32029684›Full record

Trial reportPediatrics2020

Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.

Emmanuel B Walter, Nicola P Klein, A Patricia Wodi, Wes Rountree, Christopher A Todd, Amy Wiesner, Jonathan Duffy, Paige L Marquez, Karen R Broder

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems.Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Emmanuel B WalterDepartment of Pediatrics and walte002@mc.duke.edu.
Nicola P KleinKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; and.
A Patricia WodiImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Wes RountreeDuke Human Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina.
Christopher A ToddDuke Human Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina.
Amy WiesnerKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; and.
Jonathan DuffyImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Paige L MarquezImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Karen R BroderImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Duke University · USCenters for Disease Control and Prevention · USKaiser Permanente · USNational Center for Immunization and Respiratory Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdministering inactivated influenza vaccine (IIV), 13-valent pneumococcal conjugate vaccine (PCV13), and diphtheria-tetanus-acellular pertussis (DTaP) vaccine together has been associated with increased risk for febrile seizure after vaccination. We assessed the effect of administering IIV at a separate visit from PCV13 and DTaP on postvaccination fever.

methodsIn 2017-2018, children aged 12 to 16 months were randomly assigned to receive study vaccines simultaneously or sequentially. They had 2 study visits 2 weeks apart; nonstudy vaccines were permitted at visit 1. The simultaneous group received PCV13, DTaP, and quadrivalent IIV (IIV4) at visit 1 and no vaccines at visit 2. The sequential group received PCV13 and DTaP at visit 1 and IIV4 at visit 2. Participants were monitored for fever (≥38°C) and antipyretic use during the 8 days after visits.

resultsThere were 110 children randomly assigned to the simultaneous group and 111 children to the sequential group; 90% received ≥1 nonstudy vaccine at visit 1. Similar proportions of children experienced fever on days 1 to 2 after visits 1 and 2 combined (simultaneous [8.1%] versus sequential [9.3%]; adjusted relative risk = 0.87 [95% confidence interval 0.36-2.10]). During days 1 to 2 after visit 1, more children in the simultaneous group received antipyretics (37.4% vs 22.4%;

conclusionsIn our study, delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination. Reevaluating this strategy to prevent fever using an IIV4 with a different composition in a future influenza season may be considered.

Indexed as

Diphtheria-Tetanus-acellular Pertussis VaccinesFemaleFeverHumansInfantInfluenza VaccinesMalePneumococcal Vaccines13-valent pneumococcal vaccineDiphtheria-Tetanus-acellular Pertussis VaccinesInfluenza VaccinesPneumococcal Vaccines

Identifiers

PMID32029684
PMCPMC7055925
OpenAlexW3004738625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.